企業プロフィール
Sutro Biopharma 株価・ニュース・カタリスト
- ティッカー:
- STRO
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
22.28 USD (+8.79%)
終値
最終更新: 2026年8月17日
405M USD
時価総額
株価変動の要因
As of Aug 17, 2026, STRO closed up 8.79% at $22.28. No new same-company headline was identified in the current news window.
企業概要
Next-Generation ADC Company
Sutro Biopharma develops site-specific and novel-format antibody-drug conjugates for cancer. Its cell-free platform enables optimization of antibodies, linkers, and payloads and supports both single-payload and dual-payload ADC designs.
Wholly Owned ADC Pipeline
STRO-004 is a Tissue Factor-targeting ADC with a DAR8 topoisomerase I payload in a first-in-human Phase 1 dose-escalation study. STRO-006 targets ITGB6, while STRO-227 is a dual-payload ADC directed against PTK7.
Portfolio and Partnership Model
Sutro advances wholly owned ADCs while using partnerships to validate and monetize its technology. Collaborations provide external funding and potential milestone or royalty economics while the company retains direct ownership of selected oncology programs.
Cell-Free Platform Differentiation
The cell-free manufacturing system allows precise placement of non-natural amino acids and controlled attachment of linker-payload combinations. This capability supports consistent site-specific ADCs and formats that are difficult to generate through conventional cell-based expression.
Partnered Platform Validation
The first dual-payload immune-stimulating ADC developed through Sutro’s collaboration with Astellas has entered clinical development and begun patient dosing, providing external validation of the company’s multi-payload design capabilities.
今後のカタリスト
- Initial safety, pharmacokinetic, and early activity data from the Phase 1 dose-escalation study of STRO-004 were expected in mid-2026.
- An IND submission for STRO-006 is planned in 2026.
- An IND submission for STRO-227 is planned in 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。